Novartis chief sees sales dip until mid-2013

Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

The fall in sales of the company's best-selling drug was "significant" in the United States since the end of September, when the patent ended, chief executive Joseph Jimenez told Swiss weekly SonntagsZeitung.

Sales of competing generic equivalents to the Novartis drug already caused a $2-billion (1.5-billion-euro) drop in demand for Diovan, which registered sales of $6 billion in a single year, the report added.

Rejecting the need for a fresh swathe of to counter the expected in the next three quarters, Jimenez said he planned to pursue a series of smaller measures instead.

The Basel-based company already cut 2,000 positions in late 2011, mainly in Switzerland and the US, and announced in January 2012 it was further downsizing its American operation by shedding another 1,630 positions.

Jimenez also said in the interview that the group had reviewed its range of products and expected a major rise in sales in the second half of 2013.

The patent for Diovan expired in Europe at the end of last year for Novartis, which employs around 100,000 people worldwide, according to its website.

add to favorites email to friend print save as pdf

Related Stories

New drugs shore up Novartis in Q2

Jul 19, 2012

(AP) — Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic medicines ...

Novartis announces 2,000 job losses, profits up

Oct 25, 2011

Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter.

Novartis says swine flu vaccine boosts profit

Jan 26, 2010

Swiss pharmaceutical group Novartis posted on Tuesday an 8.0-percent jump in core annual net profit for 2009, saying that business had been boosted by sales of swine flu vaccine.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments